Celgene (CELG) PT Set at $112.00 by Cantor Fitzgerald
“The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.”,” Cantor Fitzgerald’s analyst commented.
A number of other research firms have also recently commented on CELG. BMO Capital Markets increased their price target on Celgene from $148.00 to $155.00 and gave the company an outperform rating in a research note on Friday, November 17th. Oppenheimer reiterated a buy rating and issued a $170.00 price target on shares of Celgene in a research note on Friday, October 20th. Vetr upgraded Celgene from a buy rating to a strong-buy rating and set a $144.39 price target for the company in a research note on Monday, October 23rd. Cann reiterated a buy rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an underweight rating to an equal weight rating in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $129.98.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the business posted $1.58 earnings per share. The firm’s revenue was up 10.2% compared to the same quarter last year. equities research analysts predict that Celgene will post 6.71 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of CELG. Iberiabank Corp grew its holdings in Celgene by 7.5% during the second quarter. Iberiabank Corp now owns 10,901 shares of the biopharmaceutical company’s stock worth $1,416,000 after acquiring an additional 764 shares during the period. Heritage Investors Management Corp purchased a new position in Celgene during the second quarter worth approximately $2,383,000. Capital Investment Advisors LLC boosted its position in Celgene by 16.6% during the second quarter. Capital Investment Advisors LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $362,000 after purchasing an additional 397 shares in the last quarter. New England Research & Management Inc. boosted its position in Celgene by 12.4% during the second quarter. New England Research & Management Inc. now owns 11,184 shares of the biopharmaceutical company’s stock worth $1,452,000 after purchasing an additional 1,234 shares in the last quarter. Finally, Fulton Bank N.A. boosted its position in Celgene by 4.0% during the second quarter. Fulton Bank N.A. now owns 25,623 shares of the biopharmaceutical company’s stock worth $3,328,000 after purchasing an additional 996 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.